Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance

J Infect Dis. 1994 Feb;169(2):411-5. doi: 10.1093/infdis/169.2.411.

Abstract

During zidovudine therapy, human immunodeficiency virus type 1 (HIV-1) acquires a distinctive set of mutations that diminish the sensitivity of the virus to this drug in vitro. An AIDS patient is described who, while being treated with zidovudine, transmitted HIV-1 bearing a drug resistance mutation to a young woman who had never received zidovudine treatment. DNA sequencing of HIV-1 proviruses confirmed that these 2 persons shared HIV genetic variants, including a mutation at codon 70 in the reverse transcriptase gene associated with reduced in vitro sensitivity to zidovudine. This mutation persisted in the woman > 1 year in the absence of antiretroviral therapy. HIV-1 with genetic markers of zidovudine resistance can be transmitted heterosexually, but it is uncertain whether dissemination of drug-resistant virus will substantially reduce the usefulness of this drug.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Base Sequence
  • DNA Primers / chemistry
  • Drug Resistance, Microbial
  • Female
  • Genetic Variation
  • HIV Infections / transmission*
  • HIV Reverse Transcriptase
  • HIV-1 / drug effects*
  • Humans
  • Male
  • Molecular Sequence Data
  • Point Mutation
  • Polymerase Chain Reaction
  • RNA-Directed DNA Polymerase / genetics
  • Sexual Behavior
  • Time Factors
  • Zidovudine / therapeutic use*

Substances

  • DNA Primers
  • Zidovudine
  • HIV Reverse Transcriptase
  • RNA-Directed DNA Polymerase